Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Antiviral Res. 2017 Nov 4;149:1–6. doi: 10.1016/j.antiviral.2017.11.002

Figure 2. Survival curves for pritelivir (PTV) efficacy compared to acyclovir (ACV) against lethal intranasal inoculation using the ACV resistant HSV-1 strain 11360.

Figure 2

Mice were infected intranasally with the ACV resistant HSV-1 strain 11360 and treated twice daily with PTV, ACV, or vehicle (1% carboxymethylcellulose) as indicated for 7 days beginning 72 h after infection. Primary endpoint was mortality within 21 days post virus inoculation.

Overlapping lines are partially offset for better readability.